As expected in this cohort, moderate correlations between the therapy response and expression in tumor cells of a number of immunological markers of T-lymphocytes, which reflects an aberrant immunophenotype for leukemia with myeloid origin and may be associated with unfavorable outcomes [39,40], were found: CD2 (r = 0.32), CD3 (r = 0.44), and CD5 (r = 0.57) (Figure 3A). This evidence concerns the gene CD2 and neoplasm.